FDA grants 12-year exclusivity to Flublok; Emergent BioSolutions' Ebola candidate enters Ph I;

> The FDA granted 12-year exclusivity to Protein Sciences' Flublok, which means no product similar to Flublok can be approved by the FDA before Jan. 16, 2025. Release

> Emergent BioSolutions' ($EBS) investigational Ebola vaccine, produced using ProBioGen's platform, has entered clinical trials at Oxford University in the U.K. Release

> Griffith University's Institute for Glycomics has developed a combination vaccine that may beat Streptococcus A infections. Human trials may begin as early as 2016. More

> Soligenix announced data demonstrating a heat-stable formulation of an HPV vaccine. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.